menu
    • menu
    [{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"Hanx Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pucotenlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lepu Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lepu Biopharma \/ Hanx Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Lepu Biopharma \/ Hanx Biopharmaceutical"},{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"DP Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lepu Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lepu Biopharma \/ Lepu Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Lepu Biopharma \/ Lepu Biopharma"},{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"MRG007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lepu Biopharma","amount2":1.21,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.21,"dosageForm":"Undisclosed","sponsorNew":"Lepu Biopharma \/ Arrivent","highestDevelopmentStatusID":"4","companyTruncated":"Lepu Biopharma \/ Arrivent"}]

    Find Clinical Drug Pipeline Developments & Deals by Lepu Biopharma

    Menu

    Lepu Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lepu Biopharma

                            China arrow
                            ChemOutsourcing
                            Not Confirmed

                            Lepu Biopharma

                            China arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MRG007

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Arrivent

                            Deal Size : $1,207.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ArriVent, Lepu Sign Exclusive License for MRG007 in GI Cancer Treatment

                            Details : Under the terms of the agreement, Lepu Biopharma has granted ArriVent exclusive global rights to develop, manufacture and commercialize MRG007 outside of Greater China.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $47.0 million

                            January 21, 2025

                            Lead Product(s) : MRG007

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Arrivent

                            Deal Size : $1,207.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lepu Biopharma

                            China arrow
                            ChemOutsourcing
                            Not Confirmed

                            Lepu Biopharma

                            China arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : DP Technology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            DP Technology Collaborates with Lepu Biopharma to Boost ADC Drug Innovation

                            Details : The partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform and advancing the candidate ADC to the clinical stage.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : DP Technology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lepu Biopharma

                            China arrow
                            ChemOutsourcing
                            Not Confirmed

                            Lepu Biopharma

                            China arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pucotenlimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Hanx Biopharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-PD-1 Monoclonal Antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by Lepu Biopharma and...

                            Details : Puyouheng (pucotenlimab injection) is a humanized IgG4 monoclonal antibody against human PD-1, bind to PD-1 with high affinity to restore the ability of immune cells to kill cancer cells by blocking the binding of PD-1 to its ligands PD-L1 and PD-L2.

                            Product Name : Puyouheng

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 25, 2022

                            Lead Product(s) : Pucotenlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Hanx Biopharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth